Dr Vivian Emmely de Ruijter is a venture capitalist and Stanford University trained physician in healthcare technology innovation. As an investor at Intuitive Ventures she invests in products and services that advance the future of minimally invasive care with an emphasis on digital products/services, focal therapeutics, medical devices and precision diagnostics. She is a board observer for KelaHealth, Endogenex, Flywheel and MedCrypt.Prior to her current role, she served as a senior manager of the Digital and Healthcare Technology Strategy Group at Manatt, Phelps and Phillips where she provided expertise and interpretation to strategic healthcare technology initiatives and how to navigate the nuances of bringing products to market.Dr. de Ruijter also served as a life science technology innovation scientist at Stanford University and the Co-Director of the Stanford Pediatric Device Consortium in collaboration with the U.S. FDA. She was the 2016 Gruber’s Innovation Fellow at Byer’s Center of Biodesign at Stanford University after completing her training in hybrid interventional strategies at the IRCAD in France. Dr de Ruijter holds a Doctor of Medicine (MD) degree from The Erasmus University in the Netherlands, a post-doctoral designation in Biodesign, Pediatric Healthcare Technology Innovation, and Surgical Education and Innovation from Stanford University School of Medicine and School of Bioengineering, and completed the Stanford Ignite Program at the Stanford Graduate School of Business, an executive program focused on the fundamentals of business administration. She continues to teach at Stanford University and co-teaches among others MED275B, an undergraduate course in the fundamental principles of Biodesign.